Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 17/20 | 0.48 |
| ▸ | NOS1 | P29475 | 15/20 | 0.48 |
| ▸ | NOS3 | P29474 | 13/20 | 0.48 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27703858 | 0.85 | NOS2 (0.44) | NOS2NOS1NOS3VCAM1MAOA | |
| SCHEMBL2451732 | 0.84 | CYP2A6 (0.41) | NOS2NOS1NOS3VCAM1MAOA | |
| SCHEMBL5592081 | 0.81 | KDM4E (0.48) | MAOB | |
| SCHEMBL23201070 | 0.80 | NOS2 (0.50) | NOS2NOS1NOS3VCAM1ADRA1D | |
| SCHEMBL16958098 | 0.80 | NOS2 (0.47) | NOS2NOS1NOS3VCAM1MAOA | |
| SCHEMBL14115702 | 0.80 | NOS2 (0.51) | NOS2NOS1NOS3VCAM1ADRA1D | |
| SCHEMBL18419802 | 0.79 | NOS2 (0.51) | NOS2NOS1NOS3 | |
| SCHEMBL27552968 | 0.78 | GSK3B (0.37) | NOS2NOS1NOS3MAOAMAOB | |
| SCHEMBL307884 | 0.78 | NOS3 (0.47) | NOS2NOS1NOS3MAOAMAOB | |
| SCHEMBL16941902 | 0.77 | NOS2 (0.50) | NOS2NOS1NOS3VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| CN-119350433-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2025-01-24 | — | — | CN | disclosed |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| CN-112867706-B | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| CN-118373875-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-07-23 | — | — | CN | disclosed |
| WO-2010115903-A1 | CYCLIC IMIDATE LIGANDS | UNIVERSITEIT GENT (BE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-2077262-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-08 | — | — | EP | disclosed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| EP-1178802-A4 | CYCLIC AMIDINES USEFUL AS NMDA NR2B ANTAGONISTS | MERCK & CO INC (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6376530-B1 | A N-METHYLASPARTIC ACID ANTAGONIST; NERVOUS SYSTEM DISORDERS, ANALGESICS | MERCK & CO., INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1178802-A1 | CYCLIC AMIDINES USEFUL AS NMDA NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000067755-A1 | CYCLIC AMIDINES USEFUL AS NMDA NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | ADRA1D, ADRB1, ADRB2 | NOS2 548/4885NOS1 349/4885NOS3 753/4885 |
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | NOS2 4258/4885NOS1 3975/4885NOS3 4032/4885 |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | NOS2 1547/4885NOS1 1437/4885NOS3 2013/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | NOS2 4258/4885NOS1 3975/4885NOS3 4032/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | NOS2 2617/4885NOS1 3800/4885NOS3 3590/4885 |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | NOS2 2617/4885NOS1 3800/4885NOS3 3590/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | NOS2 2639/4885NOS1 3865/4885NOS3 3706/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | NOS2 4258/4885NOS1 3975/4885NOS3 4032/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | NOS2 2617/4885NOS1 3800/4885NOS3 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.